If a company's dividend payout ratio is too high, its dividend may not be sustainable. The dividend payout ratio of Cosmo Pharmaceuticals NV is 1.62, which seems too high.
During the past 13 years, the highest Dividend Payout Ratio of Cosmo Pharmaceuticals NV was 1.62. The lowest was 0.81. And the median was 0.91.
During the past 12 months, Cosmo Pharmaceuticals NV's average Dividends Per Share Growth Rate was 5.10% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Cosmo Pharmaceuticals NV was 13.40% per year. The lowest was 13.40% per year. And the median was 13.40% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Cosmo Pharmaceuticals NV Dividend Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cosmo Pharmaceuticals NV's Dividend Yield %
For the Drug Manufacturers - General subindustry, Cosmo Pharmaceuticals NV's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo Pharmaceuticals NV's Dividend Yield % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cosmo Pharmaceuticals NV's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Cosmo Pharmaceuticals NV's Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Cosmo Pharmaceuticals NV Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
EUR 1.050
2023-05-31
2023-06-01
2023-06-02
Cash Dividend
annually
EUR:CHF 0.992283
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Cosmo Pharmaceuticals NV Dividend Yield % Related Terms
Thank you for viewing the detailed overview of Cosmo Pharmaceuticals NV's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Cosmo Pharmaceuticals NV (XSWX:COPN) Business Description
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XSWX:COPN has been successfully added to your 